569250-U

Discovery^® HS C18 (3 µm) HPLC Columns

L × I.D. 5 cm × 4.6 mm, HPLC Column

• Synonym(e): Discovery RP18 HPLC Column
• UNSPSC-Code: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Eigenschaften

• product name: Discovery^® HS C18 HPLC-Säule, 3 μm particle size, L × I.D. 5 cm × 4.6 mm
• Materialien: stainless steel column
• Qualitätsniveau: 100
• Agentur: suitable for USP L1
• Produktlinie: Discovery^®
• Leistungsmerkmale: endcapped
• Hersteller/Markenname: Discovery^®
• Verpackung: 1 ea of
• Kennzeichnungsgrad: 20% Carbon loading
• Parameter: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• Methode(n): HPLC: suitable; LC/MS: suitable
• L × ID: 5 cm × 4.6 mm
• Oberflächenbereich: 300 m²/g
• Oberflächendeckung: 3.2 μmol/m²
• Verunreinigungen: <10 ppm metals
• Matrix: silica gel, high purity, spherical particle platform; fully porous particle
• Aktive Matrixgruppe: C18 (octadecyl) phase
• Partikelgröße: 3 μm
• Porengröße: 120 Å
• operating pH range: 2-8
• Anwendung(en): food and beverages
• Trenntechnik: reversed phase

Beschreibung

Anwendung

• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This study developed a robust RP-HPLC method to determine molnupiravir in various nanoformulations, showcasing its potential application in permeability studies and ensuring drug stability (Reçber et al., 2022) (Reçber et al., 2022).


• Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This research presented an HPLC-UV method for analyzing terizidone in plasma, facilitating its use in pharmacokinetic studies of patients with drug-resistant tuberculosis (Mulubwa and Mugabo, 2018) (Mulubwa and Mugabo, 2018).


• Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: The study optimized an LC method for quantifying doxorubicin in plasma and urine, crucial for pharmacokinetic, biomedical, and drug monitoring therapy applications (Maliszewska et al., 2018) (Maliszewska et al., 2018).

Leistungsmerkmale und Vorteile

• Stabile LC-MS-Trennungen mit extrem geringem Bluten
• Im analytischen bis präparativen Maßstab erhältlich
• Äußerst stabil, sichert außergewöhnliche Reproduzierbarkeit von Lauf zu Lauf und von Säule zu Säule
• Höhere Hydrophobie, für eine bessere Trennung anspruchsvoller Verbindungen

Empfohlene Produkte

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Rechtliche Hinweise

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany